Publications

Publications

Metastasis as a therapeutic target in prostate cancer: a conceptual framework

By:
Contributors: Andries Zijlstra Research Group, Katie Hebron, John D. Lewis Research Group, David Bond, PhD, Konstantin Stoletov, PhD, Srijan Raha
Am J Clin Exp Urol. 2014 Apr;2(1):45-56.

Abstract

Metastasis is the main cause of prostate cancer-associated deaths. While significant progerss has been made in the treatment of primary tumors, efficent therapies that target the metastatic spread of prostate cancer are far from clinical reality. To efficiently treat cancer we need be able to impede its spread. Unfortunately, the majority of current therapeutics approved to treat metastatic cancer were originally selected based on their ability to inhibit primary tumor growth. This inherent flaw precluded these therapies from efficiently targeting the development of secondary metastatic lesions, a process that is distinct from that of primary tumor progression. In this review we will summarize the conceptual, cellular and molecular targets that should be considered to design effective anti-metastatic therapies.

 

PubMed

Download PDF

 

APCaRI 2019 Fall Symposium

APCaRI’s 13th symposium will take place at the Banff Park Lodge, in beautiful Banff, Alberta.
Please welcome our invited speaker, Dr. Andrew Vickers; Biostatistician and Research Methodologist from Memorial Sloan Kettering Cancer Center, New York, NY.
The APCaRI Fall Symposium is always an enriching and fun event! Attendees include clinicians, scientists, clinical research personnel, trainees, benefactors and representatives of prostate cancer support groups.
See you there!
Program – 2019 APCaRI Fall Symposium_Oct 25-26

- Unknown